Danish Life Sciences Stock News

CPSE:KBHL
CPSE:KBHLInfrastructure

Copenhagen Airports (CPSE:KBHL) Margin Expansion Reinforces Bullish Infrastructure Narratives

Københavns Lufthavne (CPSE:KBHL) has opened 2026 with Q1 revenue of DKK 1.2 billion and basic EPS of DKK 19.00, set against trailing 12 month EPS of DKK 162.52. Over the past year, the company has seen revenue move from DKK 5.07 billion to DKK 5.65 billion and EPS climb from DKK 129.46 to DKK 162.52, alongside earnings growth of 26.2%. This leaves you looking at a business where higher net profit margins and solid profitability are central to the current earnings story. See our full analysis...
CPSE:FLS
CPSE:FLSMachinery

FLSmidth (CPSE:FLS) Margin Jump To 9.8% Tests Bullish Service-Led Narrative

FLSmidth (CPSE:FLS) opened 2026 with Q1 revenue of DKK 3.3b and basic EPS of DKK 18.1, set against a trailing twelve month revenue base of DKK 14.2b and EPS of DKK 24.16 that reflects a 23.3% rise in earnings over the past year. Over recent quarters the company has seen revenue move from DKK 3.7b in Q1 2025 to DKK 3.3b in Q1 2026, while quarterly basic EPS has shifted from DKK 5.44 to DKK 18.1, with that earnings trajectory feeding into higher net profit margins. Overall, these results point...
CPSE:TRMD A
CPSE:TRMD AOil and Gas

TORM Earnings Surge Tests Dividend Power And Fleet Renewal Ambitions

TORM, ticker CPSE:TRMD A, reported a strong Q1 2026 earnings surge. Geopolitical tensions and the closure of the Strait of Hormuz pushed freight rates to record highs. The company upgraded full year guidance and moved ahead with a fleet renewal plan, adding new vessels. TORM focuses on product tankers that transport refined oil products, so freight disruptions and route changes directly affect its earnings power. With key shipping lanes constrained and rerouted, demand for available,...
CPSE:DAB
CPSE:DABBanks

Exploring Undiscovered European Stocks In May 2026

As European markets navigate a period of modest gains amidst easing geopolitical tensions and strong corporate earnings, the pan-European STOXX Europe 600 Index reflects a cautiously optimistic sentiment. With potential interest rate hikes on the horizon from the European Central Bank and rising producer price inflation, investors are increasingly attentive to identifying stocks that exhibit resilience and growth potential in this dynamic environment. Exploring undiscovered gems within...
CPSE:HH
CPSE:HHBasic Materials

H+H International Q1 Loss Deepening To DKK 47 Million Tests Bullish Profitability Narratives

H+H International (CPSE:HH) opened 2026 with Q1 revenue of DKK 560 million and a reported loss per share of DKK 2.8, while on a trailing 12 month basis EPS stood at a loss of DKK 42.90 on revenue of DKK 2.63 billion. The company has seen quarterly revenue move from DKK 675 million and a loss per share of DKK 0.7 in Q1 2025 to DKK 560 million and a loss per share of DKK 2.8 in Q1 2026. Trailing 12 month net income shifted from a loss of DKK 662 million in Q4 2025 to a loss of DKK 697 million...
CPSE:NORTHM
CPSE:NORTHMMedia

North Media (CPSE:NORTHM) Q1 Loss Tests Bullish Narrative Around Fresh Trailing Profit

Q1 2026 earnings set the stage for North Media North Media (CPSE:NORTHM) has kicked off 2026 with Q1 revenue of DKK293.7 million and a basic EPS loss of DKK1.7, while trailing 12 month EPS stands at DKK8.17 on revenue of DKK1,279.2 million and net income of DKK148.2 million. Over the past year, revenue across reported periods has ranged between DKK286.4 million and DKK356.8 million per quarter, with basic EPS swinging from a loss of DKK10.12 to a gain of DKK5.29. That gives investors a wide...
CPSE:HLUN B
CPSE:HLUN BPharmaceuticals

Lundbeck (CPSE:HLUN B) Quarterly Loss Challenges Bullish Margin Expansion Narratives

H. Lundbeck (CPSE:HLUN B) has kicked off the Q1 2026 reporting season with recent quarterly figures that show Q4 2025 revenue of DKK6.1 billion and a basic EPS loss of DKK0.03, while trailing 12 month EPS sat at DKK3.22 on revenue of DKK24.6 billion. Over recent quarters, revenue has ranged from DKK5.5 billion in Q4 2024 to between DKK6.0 billion and DKK6.3 billion across the 2025 quarters. Quarterly EPS moved from DKK0.60 to DKK1.16 before the latest loss, setting up a mixed backdrop as you...
CPSE:CHEMM
CPSE:CHEMMLife Sciences

Uncovering 3 European Stocks That May Be Priced Below Intrinsic Value Estimates

As the pan-European STOXX Europe 600 Index concluded a turbulent week with modest gains, investor sentiment was buoyed by easing geopolitical tensions and robust corporate earnings across the region. However, concerns over potential U.S. tariffs on EU goods introduced some volatility into the markets. In this environment, identifying stocks that may be priced below their intrinsic value estimates can offer opportunities for investors seeking to capitalize on market inefficiencies and strong...
CPSE:COLO B
CPSE:COLO BMedical Equipment

Coloplast (CPSE:COLO B) Margin Decline Tests Bullish Earnings Growth Narratives

Coloplast (CPSE:COLO B) Q2 2026 earnings in focus Coloplast (CPSE:COLO B) has kicked off its Q2 2026 reporting with Q1 figures that put hard numbers around the story, with revenue at about DKK7.0 billion, basic EPS of DKK6.21 and net income of DKK1.40 billion. These results are backed by trailing 12 month totals of DKK27.9 billion in revenue, DKK17.70 in EPS and DKK4.0 billion in net income. Over recent quarters the company has seen revenue hover in a tight band between DKK6.93 billion and...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Assessing Novo Nordisk’s Valuation As Wegovy STEP UP Data Supports Deeper Fat Loss And Broader Health Benefits

New clinical data around Wegovy’s higher 7.2 mg dose is back in focus after Novo Nordisk (CPSE:NOVO B) released STEP UP sub-analyses showing deep, largely fat-driven weight loss and supportive real-world outcomes in women. See our latest analysis for Novo Nordisk. The new Wegovy data arrives after a busy few weeks for Novo Nordisk, with first quarter 2026 earnings, new distribution tie ups for Ozempic and oral GLP 1s, and the transfer of its Parkinson’s cell therapy program to an AI focused...
CPSE:ROCK B
CPSE:ROCK BBuilding

Rockwool (CPSE:ROCK B) Is Up 6.2% After Raising 2026 Growth Guidance And Capex Plans

Rockwool A/S recently raised its 2026 revenue growth guidance to 3%–6% from 2%–4%, maintained its EBIT margin outlook at 13%–14%, and increased planned 2026 investments to about €700.00 million after seeing volume demand improve from March into the second quarter. The updated guidance suggests management now sees stronger momentum in underlying demand and is prepared to commit more capital to support that higher activity level through the rest of the year. We will now examine how Rockwool’s...
CPSE:TRIFOR
CPSE:TRIFORIT

European Growth Companies With High Insider Ownership

The European market has experienced a volatile but ultimately positive week, with the pan-European STOXX Europe 600 Index showing modest gains amid easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. have added pressure to the markets, creating an environment where insider ownership can be a reassuring factor for investors looking at growth companies. In such conditions, stocks with high insider ownership might offer...
CPSE:BAVA
CPSE:BAVABiotechs

A Look At Bavarian Nordic (CPSE:BAVA) Valuation After New US$97 Million Vaccine Contract And Guidance Upgrade

Bavarian Nordic (CPSE:BAVA) is back in focus after securing US$97 million in contract options from the U.S. government for freeze dried smallpox vaccines and lifting its full year 2026 financial guidance. See our latest analysis for Bavarian Nordic. At a share price of DKK194.6, Bavarian Nordic has seen a 1-year total shareholder return of 16.84%, while the 5-year total shareholder return is down 28.27%. This suggests that recent momentum has improved compared with a weaker longer term...
CPSE:DFDS
CPSE:DFDSShipping

Assessing DFDS (CPSE:DFDS) Valuation After Narrowed Q1 2026 Loss And Maintained Guidance

DFDS (CPSE:DFDS) has drawn investor attention after reporting first quarter 2026 results that showed a narrower net loss and confirming full year EBIT guidance, supported by comments on improving freight traffic and profitability recovery. See our latest analysis for DFDS. The earnings update and confirmed EBIT guidance have arrived alongside a sharp improvement in momentum, with the share price delivering a 27.05% 1 month return and a 49.47% year to date share price return. The 1 year total...